The Impact of Tumor-associated Inflammatory Adhesion on the Prognosis of Colon Cancer Patients: a Study Based on the SEER and Chinese Multi-center Databases
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 229
- 试验地点
- 1
- 主要终点
- Overall survival time (OS)
研究概览
简要总结
The purpose of this study is to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients.
详细描述
In some colon cancer patients, although adhesions between the tumor tissue and surrounding organs are found during surgery, postoperative pathology confirms that the tumor has not directly invaded the adhered organs; instead, the adhesions are caused by tumor-associated inflammation. This condition is defined as tumor-associated inflammatory adhesion.
Currently, the impact of tumor-associated inflammatory adhesion on patient prognosis is still unclear. This study aims to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients through the Surveillance, Epidemiology, and End Results (SEER) and Chinese multi-center databases.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient was pathologically diagnosed as colon adenocarcinoma by endoscopic biopsy before operation.
- •All patients were considered to have tumors invading adjacent organs during surgery
- •All patients underwent radical surgery.
排除标准
- •Patients with distant metastasis, recurrent colon cancer and pT4b CRC were excluded.
结局指标
主要结局
Overall survival time (OS)
时间窗: up to 10 years
OS, defined as the time from the first diagnosis to death from any cause or the last follow-up for surviving patients
Cancer-specific survival time (CSS)
时间窗: up to 10 years
CSS refers to the duration from diagnosis of a tumor until the patient succumbs to the tumor, excluding deaths from other causes.
Recurrence free survival time (RFS)
时间窗: up to 10 years
RFS is the time from the time a patient achieved R0 resection after surgery to the time of recurrence or the end of follow-up.
次要结局
未报告次要终点
研究者
Jianqiang Tang
Associate professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences